FDA — authorised 24 July 1957
- Marketing authorisation holder: MEDPOINTE PHARM HLC
- Status: approved
FDA authorised Niaspan on 24 July 1957
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 24 July 1957.
MEDPOINTE PHARM HLC holds the US marketing authorisation.